231 related articles for article (PubMed ID: 34544399)
1. Late-onset hypophysitis after discontinuation of nivolumab treatment for advanced skin melanoma: a case report.
Antoniou S; Bazazo G; Röckl L; Papadakis M; Berg C
BMC Endocr Disord; 2021 Sep; 21(1):191. PubMed ID: 34544399
[TBL] [Abstract][Full Text] [Related]
2. Late-onset isolated adrenocorticotropic hormone deficiency caused by nivolumab: a case report.
Takeno A; Yamamoto M; Morita M; Tanaka S; Kanazawa I; Yamauchi M; Kaneko S; Sugimoto T
BMC Endocr Disord; 2019 Feb; 19(1):25. PubMed ID: 30782163
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab-induced hypophysitis causing secondary adrenal insufficiency after transient ACTH elevation.
Sekizaki T; Kameda H; Oba C; Yong Cho K; Nakamura A; Miyoshi H; Osawa T; Shinohara N; Atsumi T
Endocr J; 2019 Oct; 66(10):937-941. PubMed ID: 31217401
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma.
Okano Y; Satoh T; Horiguchi K; Toyoda M; Osaki A; Matsumoto S; Tomaru T; Nakajima Y; Ishii S; Ozawa A; Shibusawa N; Shimada T; Higuchi T; Chikamatsu K; Yamada M
Endocr J; 2016 Oct; 63(10):905-912. PubMed ID: 27440480
[TBL] [Abstract][Full Text] [Related]
5. Onset of fulminant type 1 diabetes mellitus following hypophysitis after discontinuation of combined immunotherapy. A case report.
Boswell L; Casals G; Blanco J; Jiménez A; Aya F; de Hollanda A; Halperin I; Arance AM; Mora M; Hanzu FA
J Diabetes Investig; 2021 Dec; 12(12):2263-2266. PubMed ID: 34048145
[TBL] [Abstract][Full Text] [Related]
6. Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature.
Ohara N; Kobayashi M; Ohashi K; Ito R; Ikeda Y; Kawaguchi G; Yoneoka Y; Hasegawa G; Takada T
J Med Case Rep; 2019 Mar; 13(1):88. PubMed ID: 30909965
[TBL] [Abstract][Full Text] [Related]
7. Hypophysitis secondary to pembrolizumab: a case report and review of the literature.
Montero Pérez O; Sánchez Escudero L; Guzmán Ramos MI; Aviñó Tarazona V
Anticancer Drugs; 2022 Jan; 33(1):94-99. PubMed ID: 34261922
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab-induced Hypophysitis, Secondary Adrenal Insufficiency and Destructive Thyroiditis in a Patient with Lung Adenocarcinoma.
Mishima Y; Fukaishi T; Inase N; Isogai S
Intern Med; 2019 Mar; 58(5):693-697. PubMed ID: 30449786
[TBL] [Abstract][Full Text] [Related]
9. Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis.
Thapi S; Leiter A; Galsky M; Gallagher EJ
J Immunother Cancer; 2019 Sep; 7(1):248. PubMed ID: 31511065
[TBL] [Abstract][Full Text] [Related]
10. Checkpoint Inhibitor-Associated Hypophysitis.
Chang LS; Yialamas MA
J Gen Intern Med; 2018 Jan; 33(1):125-127. PubMed ID: 28770379
[No Abstract] [Full Text] [Related]
11. Nivolumab-induced hypophysitis leading to hypopituitarism and secondary empty sella syndrome in a patient with non-small cell lung cancer.
Chang J; Tran J; Kamel D; Basu A
BMJ Case Rep; 2019 Mar; 12(3):. PubMed ID: 30850565
[TBL] [Abstract][Full Text] [Related]
12. Predicting development of ipilimumab-induced hypophysitis: utility of T4 and TSH index but not TSH.
Siddiqui MS; Lai ZM; Spain L; Greener V; Turajlic S; Larkin J; Morganstein DL
J Endocrinol Invest; 2021 Jan; 44(1):195-203. PubMed ID: 32449093
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab-induced hypothyroidism followed by isolated ACTH deficiency.
Martins Machado C; Almeida Santos L; Barroso A; Oliveira MJ
BMJ Case Rep; 2019 Aug; 12(8):. PubMed ID: 31466960
[TBL] [Abstract][Full Text] [Related]
14. An autopsy case study of lymphocytic hypophysitis induced by nivolumab treatment for esophageal malignant melanoma.
Okabe N; Kobayashi T; Furuse J; Fujiwara M; Kamma H
Pathol Int; 2021 Dec; 71(12):831-836. PubMed ID: 34506687
[TBL] [Abstract][Full Text] [Related]
15. Isolated Adrenocorticotropic Hormone Deficiency in Melanoma Patients Treated with Nivolumab.
Kitano S; Tatsuno K; Ishibe J; Shimauchi T; Fujiyama T; Ito T; Ogawa N; Tokura Y
Acta Derm Venereol; 2018 Jul; 98(7):704-705. PubMed ID: 29405244
[No Abstract] [Full Text] [Related]
16. Immunotherapy-induced autoimmune hypophysitis.
Valecha G; Pant M; Ibrahim U; Atallah JP
J Oncol Pharm Pract; 2019 Jan; 25(1):217-220. PubMed ID: 28825378
[TBL] [Abstract][Full Text] [Related]
17. Isolated adrenocorticotropic hormone deficiency possibly caused by nivolumab in a metastatic melanoma patient.
Fujimura T; Kambayashi Y; Furudate S; Kakizaki A; Hidaka T; Haga T; Hashimoto A; Morimoto R; Aiba S
J Dermatol; 2017 Mar; 44(3):e13-e14. PubMed ID: 27440178
[No Abstract] [Full Text] [Related]
18. Case of hypophysitis caused by nivolumab.
Ishikawa M; Oashi K
J Dermatol; 2017 Jan; 44(1):109-110. PubMed ID: 27178147
[No Abstract] [Full Text] [Related]
19. Nivolumab induced hypophysitis in a patient with recurrent non-small cell lung cancer.
Kajal S; Gupta P; Ahmed A; Gupta A
Drug Discov Ther; 2021 Sep; 15(4):218-221. PubMed ID: 34456195
[TBL] [Abstract][Full Text] [Related]
20. Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis.
Faje A; Reynolds K; Zubiri L; Lawrence D; Cohen JV; Sullivan RJ; Nachtigall L; Tritos N
Eur J Endocrinol; 2019 Sep; 181(3):211-219. PubMed ID: 31176301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
